
Abcuro shared Phase 2/3 MUSCLE study results for ulviprubart in inclusion body myositis at GCOM 2026.
Abcuro Presents Results from Phase 2/3 MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis at GCOM 2026 Abcuro, Inc., a clinical stage biotechnology company, today presented results at the 6th Global Conference on Myositis (GCOM) meeting, being held March 23-26, 2026…













